Traders should expect a sharp decline in liquidity and institutional selling pressure as the stock moves to OTC Markets on August 31. The ongoing strategic alternatives process (initiated March 2026) could result in a sale or merger, but there is no assurance of any transaction. Monitor for a Form 25-NSE filing and any update on the strategic review.
Price Chart
Executive Summary
BioAtla received final delisting notice from Nasdaq on August 26, 2026, after the Nasdaq Listing Council affirmed the Hearings Panel's prior decision to delist the company's common stock. Trading on Nasdaq will be suspended at the open on August 31, 2026, unless the Nasdaq Board calls the matter for review. The stock is expected to move to OTC Markets under the same ticker (BCAB), which will severely reduce liquidity and institutional ownership for this $5M market-cap biotech.
Key Facts
- Nasdaq Listing Council affirmed delisting determination on August 26, 2026
- Trading suspension on Nasdaq effective at opening on August 31, 2026
- Delisting based on non-compliance with $1.00 bid price rule (5550(a)(2)) and $2.5M stockholders' equity requirement (5550(b)(1))
- Stock expected to move to OTC Markets under symbol BCAB
- Company initiated a formal strategic alternatives process in March 2026, which remains ongoing
- Market cap is approximately $5M
Financial Impact
Delisting from Nasdaq to OTC Markets will severely reduce liquidity and institutional ownership; no specific dollar impact quantified in filing
Risk Factors
- Complete loss of Nasdaq listing and associated institutional ownership
- OTC Markets may not develop sufficient trading volume or price discovery
- Strategic alternatives process may not result in any transaction
- Going concern risk as company needs additional funding to continue operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (BCAB) — Batch item 1 | 0001539497-26-002373 |
| Document: 0001539497-26-002373-index.html | 0001539497-26-002373 |
| Document: 0001539497-26-002373.txt | 0001539497-26-002373 |
| 8-K Filing (BCAB) — Batch item 4 | 0001539497-26-002373 |
| Document: 0001539497-26-002373-index.html | 0001539497-26-002373 |
| Document: 0001539497-26-002373.txt | 0001539497-26-002373 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 6d ago | S-1 | $1.74 | awaiting T+20 | — | $1.71 (+1.44%) |
Oct 19, 2026 6d ago | 8-K | $1.74 | awaiting T+20 | — | $1.71 (+1.44%) |
Aug 28, 2026 8w ago | 8-K | $1.74 $1.74 | · 0.00% | ▲ +0.26% | $1.71 (+1.44%) |
Mar 31, 2026 29w ago | 8-K | $6.75 $4.04 | ▲ +40.15% | ▲ +49.87% | $1.71 (+74.67%) |
Mar 2, 2026 33w ago | DEFA14A | $10.20 $7.70 | ▼ −24.51% | ▼ −16.57% | $1.71 (−83.24%) |
Mar 2, 2026 33w ago | Press Release | $10.20 $7.70 | ▲ +24.51% | ▲ +16.57% | $1.71 (+83.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers